CoChat

GLP-1-directed NMDA receptor antagonism for obesity treatment

Open access
Petersen, Jonas, Ludwig, Mette Q., Juozaityte, Vaida, Ranea-Robles, Pablo, Svendsen, Charlotte, Hwang, Eunsang, Kristensen, Amalie W., Fadahunsi, Nicole, Lund, Jens, Breum, Alberte W., Mathiesen, Cecilie V., Sachs, Luisa, Moreno-Justicia, Roger, Rohlfs, Rebecca, Ford, James C., Douros, Jonathan D., Finan, Brian, Portillo, Bryan, Grose, Kyle, Petersen, Jacob E., Trauelsen, Mette, Feuchtinger, Annette, DiMarchi, Richard D., Schwartz, Thue W., Deshmukh, Atul S., Thomsen, Morten B., Kohlmeier, Kristi A., Williams, Kevin W., Pers, Tune H., Frølund, Bente, Strømgaard, Kristian, Klein, Anders B., Clemmensen, Christoffer · 2024 · Nature
Cited by 89

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

The N-methyl-d-aspartate (NMDA) receptor is a glutamate-activated cation channel that is critical to many processes in the brain. Genome-wide association studies suggest that glutamatergic neurotransmission and NMDA receptor-mediated synaptic plasticity are important for body weight homeostasis 1. Here we report the engineering and preclinical development of a bimodal molecule that integrates NMDA receptor antagonism with glucagon-like peptide-1 (GLP-1) receptor agonism to effectively reverse obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease. GLP-1-directed delivery of the NMDA receptor antagonist MK-801 affects neuroplasticity in the hypothalamus and brainstem. Importantly, targeting of MK-801 to GLP-1 receptor-expressing brain regions circumvents adverse physiological and behavioural effects associated with MK-801 monotherapy. In summary, our approach demonstrates the feasibility of using peptide-mediated targeting to achieve cell-specific ionotropic receptor modulation and highlights the therapeutic potential of unimolecular mixed GLP-1 receptor agonism and NMDA receptor antagonism for safe and effective obesity treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-07419-8

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 89

Metadata

Authors
Petersen, J., Ludwig, M. Q., Juozaityte, V., Ranea-Robles, P., Svendsen, C., Hwang, E., Kristensen, A. W., Fadahunsi, N., Lund, J., Breum, A. W., Mathiesen, C. V., Sachs, L., Moreno-Justicia, R., Rohlfs, R., Ford, J. C., Douros, J. D., Finan, B., Portillo, B., Grose, K., Petersen, J. E., Trauelsen, M., Feuchtinger, A., DiMarchi, R. D., Schwartz, T. W., Deshmukh, A. S., Thomsen, M. B., Kohlmeier, K. A., Williams, K. W., Pers, T. H., Frølund, B., Strømgaard, K., Klein, A. B., & Clemmensen, C.
Venue
Nature
Published
2024-05-15
Volume
629
Issue
8014
Pages
1133-1141
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4396939146
Cited by
89
References
19
FWCI
15.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1-directed NMDA receptor antagonism for obesity treatment. https://app.cochat.ai/papers/10.1038/s41586-024-07419-8
The paper
Petersen, J., Ludwig, M. Q., Juozaityte, V., Ranea-Robles, P., Svendsen, C., Hwang, E., Kristensen, A. W., Fadahunsi, N., Lund, J., Breum, A. W., Mathiesen, C. V., Sachs, L., Moreno-Justicia, R., Rohlfs, R., Ford, J. C., Douros, J. D., Finan, B., Portillo, B., Grose, K., . . . Clemmensen, C. (2024). GLP-1-directed NMDA receptor antagonism for obesity treatment. Nature. https://doi.org/10.1038/s41586-024-07419-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.